Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
Open Access
- 11 August 2023
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-11
Abstract
Existing guidance regarding clinically informed germline testing for patients with cancer is effective for evaluation of classic hereditary cancer syndromes and established gene/cancer type associations. However, current screening methods may miss patients with rare, reduced penetrance, or otherwise occult hereditary risk. Secondary finding of suspected germline variants that may confer inherited cancer risk via tumor comprehensive genomic profiling (CGP) has the potential to help address these limitations. However, reporting practices for secondary finding of germline variants are inconsistent, necessitating solutions for transparent and coherent communication of these potentially important findings. A workflow for improved confidence detection and clear reporting of potential pathogenic germline variants (PPGV) in select cancer susceptibility genes (CSG) was applied to a research dataset from real-world clinical tumor CGP of > 125,000 patients with advanced cancer. The presence and patterns of PPGVs identified across tumor types was assessed with a focus on scenarios in which traditional clinical germline evaluation may have been insufficient to capture genetic risk. PPGVs were identified in 9.7% of tumor CGP cases using tissue- and liquid-based assays across a broad range of cancer types, including in a number of “off-tumor” contexts. Overall, PPGVs were identified in a similar proportion of cancers with National Comprehensive Cancer Network (NCCN) recommendations for germline testing regardless of family history (11%) as in all other cancer types (9%). These findings suggest that tumor CGP can serve as a tool that is complementary to traditional germline genetic evaluation in helping to ascertain inherited susceptibility in patients with advanced cancer.Keywords
This publication has 59 references indexed in Scilit:
- Challenges and disparities in the application of personalized genomic medicine to populations with African ancestryNature Communications, 2016
- Analysis of protein-coding genetic variation in 60,706 humansNature, 2016
- Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary FindingsClinical Cancer Research, 2016
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolAnnals of Oncology, 2016
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer SusceptibilityJournal of Clinical Oncology, 2015
- Cancer Genomics and Inherited RiskJournal of Clinical Oncology, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Clinical significance of large rearrangements in BRCA1 and BRCA2Cancer, 2012
- Hereditary Cancer Predisposition SyndromesJournal of Clinical Oncology, 2005